全文获取类型
收费全文 | 68022篇 |
免费 | 4991篇 |
国内免费 | 1652篇 |
专业分类
耳鼻咽喉 | 412篇 |
儿科学 | 1758篇 |
妇产科学 | 1741篇 |
基础医学 | 5564篇 |
口腔科学 | 1206篇 |
临床医学 | 8287篇 |
内科学 | 6903篇 |
皮肤病学 | 742篇 |
神经病学 | 2476篇 |
特种医学 | 2856篇 |
外国民族医学 | 21篇 |
外科学 | 3964篇 |
综合类 | 15363篇 |
现状与发展 | 12篇 |
一般理论 | 2篇 |
预防医学 | 3382篇 |
眼科学 | 1055篇 |
药学 | 3115篇 |
95篇 | |
中国医学 | 12233篇 |
肿瘤学 | 3478篇 |
出版年
2024年 | 101篇 |
2023年 | 745篇 |
2022年 | 1434篇 |
2021年 | 2533篇 |
2020年 | 2755篇 |
2019年 | 1796篇 |
2018年 | 1680篇 |
2017年 | 2180篇 |
2016年 | 2574篇 |
2015年 | 2139篇 |
2014年 | 4990篇 |
2013年 | 4477篇 |
2012年 | 4609篇 |
2011年 | 4909篇 |
2010年 | 3939篇 |
2009年 | 3280篇 |
2008年 | 3171篇 |
2007年 | 3480篇 |
2006年 | 3187篇 |
2005年 | 2770篇 |
2004年 | 2372篇 |
2003年 | 2169篇 |
2002年 | 1786篇 |
2001年 | 1635篇 |
2000年 | 1258篇 |
1999年 | 969篇 |
1998年 | 875篇 |
1997年 | 858篇 |
1996年 | 766篇 |
1995年 | 701篇 |
1994年 | 663篇 |
1993年 | 595篇 |
1992年 | 496篇 |
1991年 | 418篇 |
1990年 | 355篇 |
1989年 | 284篇 |
1988年 | 320篇 |
1987年 | 238篇 |
1986年 | 210篇 |
1985年 | 198篇 |
1984年 | 131篇 |
1983年 | 90篇 |
1982年 | 97篇 |
1981年 | 96篇 |
1980年 | 80篇 |
1979年 | 71篇 |
1978年 | 47篇 |
1977年 | 27篇 |
1976年 | 31篇 |
1975年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
Susanna Zanutto Chiara Maura Ciniselli Antonino Belfiore Mara Lecchi Enzo Masci Gabriele Delconte Massimo Primignani Giulia Tosetti Marco Dal Fante Linda Fazzini Aldo Airoldi Marcello Vangeli Francesca Turpini Giovanni Giuseppe Rubis Passoni Paolo Viaggi Monica Arena Roberta Ilaria Olimpia Motta Anna Maria Cantù Cristiano Crosta Giuseppe De Roberto Francesca Iannuzzi Andrea Cassinotti Valentina Dall'Olio Laura Tizzoni Gabriella Sozzi Emanuele Meroni Luigi Bisanti Marco Alessandro Pierotti Paolo Verderio Manuela Gariboldi 《International journal of cancer. Journal international du cancer》2020,146(4):1164-1173
Colorectal cancer (CRC) screening programs help diagnose cancer precursors and early cancers and help reduce CRC mortality. However, currently recommended tests, the fecal immunochemical test (FIT) and colonoscopy, have low uptake. There is therefore a pressing need for screening strategies that are minimally invasive and consequently more acceptable to patients, most likely blood based, to increase early CRC identification. MicroRNAs (miRNAs) released from cancer cells are detectable in plasma in a remarkably stable form, making them ideal cancer biomarkers. Using plasma samples from FIT-positive (FIT+) subjects in an Italian CRC screening program, we aimed to identify plasma circulating miRNAs that detect early CRC. miRNAs were initially investigated by quantitative real-time PCR in plasma from 60 FIT+ subjects undergoing colonoscopy at Fondazione IRCCS Istituto Nazionale dei Tumori, then tested on an internal validation cohort (IVC, 201 cases) and finally in a large multicenter prospective series (external validation cohort [EVC], 1121 cases). For each endoscopic lesion (low-grade adenoma [LgA], high-grade adenoma [HgA], cancer lesion [CL]), specific signatures were identified in the IVC and confirmed on the EVC. A two-miRNA-based signature for CL and six-miRNA signatures for LgA and HgA were selected. In a multivariate analysis including sex and age at blood collection, the areas under the receiver operating characteristic curve (95% confidence interval) of the signatures were 0.644 (0.607–0.682), 0.670 (0.626–0.714) and 0.682 (0.580–0.785) for LgA, HgA and CL, respectively. A miRNA-based test could be introduced into the FIT+ workflow of CRC screening programs so as to schedule colonoscopies only for subjects likely to benefit most. 相似文献
22.
2015年中华医学会感染病学分会艾滋病学组发布了第三版《艾滋病诊疗指南》。新版指南强调抗病毒治疗时点前移:一旦成人确诊感染人类免疫缺陷病毒(HIV), 若无禁忌宜尽早启动抗HIV治疗。对于合并机会性感染的HIV感染者, 在感染控制、病情稳定后也应及早开始抗病毒治疗。尤其强调HIV合并结核患者在CD4阳性淋巴细胞数少于200/μL的情况下, 建议抗结核两周内即开始抗病毒治疗。在抗HIV治疗用药中, 淘汰了一些毒副作用大、依从性较差的药物, 如司他夫定、去羟肌苷、茚地那韦等, 优选抗病毒效力强、服药方便的组合, 如拉米夫定、替诺福韦、依非韦伦组合。对于HIV感染的婴幼儿, 亦主张及早抗HIV治疗。对于五岁以内的幼儿, 主张确诊后即启动抗病毒治疗。对于HIV感染的孕产妇, 建议尽快予以全程、联合抗HIV治疗, 寓防于治。 相似文献
23.
支气管哮喘是由多种细胞和细胞组分参与的气道慢性炎症性疾病,其气道炎症反应的复杂性,给临床诊断和治疗带来了困难[1]。2009年全球哮喘防治倡议(GINA)第一次提出“表型”这一概念,并提出基于表型分类有助于哮喘治疗及判断预后[2]。中医药治疗哮喘有其独特优势,但辨证分型缺乏明确统一的客观化、量化指标。 相似文献
24.
25.
ObjectiveThis study used a prospective cohort study to observe the effect of triple-negative breast cancer on the 2-year disease-free survival rate with or without “TCM formula”.MethodsFrom November 1 st, 2016, the first patient was enrolled in the cohort study. A total of 356 patients were enrolled on January 30, 2019. Among them, 154 cases were followed up for 2 years. During the follow-up, there were 6 cases of shedding, so 6 cases were affected. A total of 148 cases were included in the analysis, including 73 in the exposed group and 75 in the non-exposed group. The exposed group was given “TCM formula” on the basis of standardized treatment, and the non-exposed group was treated with simple triple-negative breast cancer. The two groups visited each of the three months. The interview included safety examination (hematology and imaging). The endpoint was the difference in 2-year invasive disease-free survival between the exposed and non-exposed groups and the safety of the “TCM formula”.ResultsThere were 6 cases of shedding during the experiment and the shedding rate was 3.9 %. The 2-year rate of invasive disease-free survival in the exposed team was 88.7 % and the non-exposed group was 82.5 %. Logistic multivariate regression analysis predicted that “TCM formula” could reduce the disease-related recurrence and metastasis rate by 11 % (OR = 0.89, 95 % CI 0.37−0.956, P<0.05). Through K–M survival analysis, TNBC patients with age ≤35 years and regional lymph node stage N1 may be the benefit group of “TCM formula”(P<0.05). During the study, the incidence of total adverse events was 8.2 % in the exposed group, mainly manifested as stomach discomfort, diarrhea, and hepatocyte damage.Conclusion1. In the exposed group, the two-year rate of invasive disease-free survival increased by 6.2 % compared with the non-exposed group(P>0.05). 2. According to K–M survival analysis, TNBC patients with age ≤35 years and regional lymph node metastasis to N1 may be potential beneficiaries of “TCM formula”. 3. “TCM Formula” is safe and tolerable to most patients. 相似文献
26.
27.
《Ophthalmology》2020,127(11):1498-1506
28.
Moises Rodriguez-Gonzalez Antonio Moruno Tirado Reza Hosseinpour Jose Santos de Soto 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(4):350-356
Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) is a rare congenital condition. It responds well to early diagnosis and treatment, but otherwise the prognosis is poor. We present our case series of 12 patients (mean age, 2 ± 2.58 yr; age range, 2 mo–8 yr), emphasizing the diagnostic process and discussing our surgical results. The diagnosis of ALCAPA should be suspected in infants who have dilated cardiomyopathy with electrocardiographic changes that suggest ischemia, and in older children who have isolated mitral regurgitation. When clinical suspicion is high, the results of 2-dimensional echocardiography combined with color-flow Doppler studies in expert hands can establish the diagnosis, thus avoiding angiography in critically ill infants. The treatment of choice in our patients was transfer and reimplantation of the left coronary artery onto the ascending aorta. There were 2 deaths: both were infants in extremis who underwent emergency surgery. An older child with severe ventricular dysfunction was given mechanical ventricular assistance and then heart transplantation. As of this report, all 10 survivors remained well and asymptomatic. 相似文献
29.
淋巴管作为循环系统的重要组成部分之一,具有调节机体体液稳态,协助免疫监视和肠道脂质吸收等重要作用。淋巴管新生是机体生理和病理过程中维持脉管系统结构和功能正常的重要手段,淋巴管新生调控对于防治肿瘤、心血管等诸多疾病有着潜在的临床转化意义;淋巴回流功能则与关节炎症等疾病发病机制关系密切。在循环系统中,相较于中医药调控血管相关疾病的发病机制已取得很大进展,近年来对于淋巴管的研究则明显相对滞后。本文从中医药作用于淋巴管新生及回流功能角度对这一领域的研究进展作一综述,以期为临床上中医药治疗相关疾病提供新的思路与方法。 相似文献
30.